Glucon, based in Santa Clara, California, is developing a device to measure blood glucose levels in hospital patients. 3i led the recent round alongside Sequel Ventures and Hunt Bioventures joining existing investors including Giza. Studies have shown that close monitoring of blood glucose can reduce mortality rates in intensive care patients. Today, the practice of taking finger-stick measurements is both time consuming for nurses and inconvenient for patients. Glucon's device will automate the process to take blood readings and provide a frequent read-out for physicians both freeing up valuable nurse time and improving healthcare economics and importantly, patient outcomes.

Print this page